Analysis of drug use in medical institutions of Guangdong area during 2017-2022

ZHENG Yating; KE Yongbo; LIU Yuheng; WANG Yong; ZHENG Zhihua

doi:10.6039/j.issn.1001-0408.2023.21.15

您当前的位置：

首页 >

文章列表页 >

Analysis of drug use in medical institutions of Guangdong area during 2017-2022

更新时间：2023-11-10

- Analysis of drug use in medical institutions of Guangdong area during 2017-2022
- ZHONGGUO YAOFANG Vol. 34, Issue 21, Pages: 2654-2657(2023)
- 作者机构：
  
  1.广东省妇幼保健院人力资源科，广州　511442
  2.广东省药学会，广州　510080
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.21.15
  CLC： R95
- Published：15 November 2023，
  
  Received：01 September 2023，
  
  Revised：26 September 2023，
扫描看全文
郑雅婷,柯涌波,刘宇恒等.2017－2022年广东地区医疗机构用药情况分析[J].中国药房,2023,34(21):2654-2657.

ZHENG Yating,KE Yongbo,LIU Yuheng,et al.Analysis of drug use in medical institutions of Guangdong area during 2017-2022[J].ZHONGGUO YAOFANG,2023,34(21):2654-2657.
郑雅婷,柯涌波,刘宇恒等.2017－2022年广东地区医疗机构用药情况分析[J].中国药房,2023,34(21):2654-2657. DOI： 10.6039/j.issn.1001-0408.2023.21.15.

ZHENG Yating,KE Yongbo,LIU Yuheng,et al.Analysis of drug use in medical institutions of Guangdong area during 2017-2022[J].ZHONGGUO YAOFANG,2023,34(21):2654-2657. DOI： 10.6039/j.issn.1001-0408.2023.21.15.

摘要

目的

分析2017－2022年广东地区医疗机构的用药情况，为政府部门、医保部门、制药企业、药品销售企业及医院等制定政策以及药品的生产、销售及采购提供参考依据。

方法

采用回顾性分析方法，以2017－2022年广东省医院用药信息网数据为基础，对这6年间均在网的118家医疗机构的药品采购金额以及在所有入网医疗机构采购药品中14大类药品的分布情况、药品生产企业销售金额等进行统计分析。

结果

2017－2022年，广东地区均在网的118家医疗机构药品采购金额呈现出增长-负增长-缓慢增长的趋势；在14大类药品中采购金额排名前5位的均为抗感染药物、心血管系统用药、神经系统药物、抗恶性肿瘤药物和作用于消化系统药物；在采购金额排名前200位的药品中，抗感染药物、抗恶性肿瘤药物、心血管系统用药这3大类药物占主要地位；采购金额排名前10位的药品主要为抗恶性肿瘤药物、心血管系统用药；在广东地区医疗机构销售药品金额排名前3位的均是国外药品生产企业。

结论

在广东地区，医疗机构药品采购金额增长逐渐放缓，抗感染药物的使用量仍然较大，慢性病防治仍需高度关注和重视，国外制药企业在医疗机构的销售金额处于领先地位。

Abstract

OBJECTIVE

To analyze the situation of drug use in medical institutions of Guangdong area from 2017 to 2022， and to provide reference for the production， sale and procurement of drugs by government departments， medical insurance departments， pharmaceutical enterprises， drug sales enterprises and hospitals.

METHODS

Using the retrospective analysis method， based on original data from Guangdong hospital information network from 2017 to 2022， statistical analysis was conducted on the drug procurement amount of 118 medical institutions that had been online for the past 6 years， as well as the distribution of 14 major categories of drugs among all purchased drugs by online medical institutions， and sales amount of drug production enterprises.

RESULTS

The drug procurement amount of 118 medical institutions that had been online in Guangdong area from 2017 to 2022 showed a growth-negative growth-slow growth trend. Among the 14 major categories of drugs， the top 5 drugs in the list of consumption sum were anti-infective drugs， cardiovascular drugs， nervous system drugs， anti-tumor drugs， and digestive system drugs； among the top 200 drugs in terms of procurement amount， three major categories of drugs， namely the anti-infective drugs， anti-tumor drugs and cardiovascular system drugs， occupied the main position. The top 10 drugs in the list of procurement amounts were mainly anti-tumor drugs and cardiovascular system drugs； foreign manufacturers occupied the top 3 places in the list of sales amounts in medical institutions of Guangdong area.

CONCLUSIONS

In Guangdong area， the growth of drug procurement amount in medical institutions is gradually slowing down， the usage of anti-infective drugs is still abundant， the prevention and treatment of chronic diseases need great attention， and foreign pharmaceutical companies are in a leading position in the sales amount of medical institutions.

关键词

广东地区医院用药销售金额用药趋势

Keywords

hospital medicationsales amountdrug use trends

references

国务院办公厅.国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知 [EB/OL].（2019-01-01）[2023-09-10]. https：//www.gov.cn/gongbao/content/2019/content5361793.htmhttps://www.gov.cn/gongbao/content/2019/content5361793.htm.

General Office of the State Council of the People’s Republic of China. General Office of the State Council of the People’s Republic of China on issuing the pilot plan for centralized procurement and use of national organized drugs[EB/OL].（2019-01-01）[2023-09-10]. https：//www.gov.cn/gongbao/content/2019/content5361793.htmhttps://www.gov.cn/gongbao/content/2019/content5361793.htm.

国家医疗保障局.国家医疗保障局等九部门印发关于国家组织药品集中采购和使用试点扩大区域范围的实施意见[EB/OL].（2019-09-30）[2023-09-10]. http：//www.nhsa.gov.cn/art/2019/9/30/art_52_1816.htmlhttp://www.nhsa.gov.cn/art/2019/9/30/art_52_1816.html.

National Healthcare Security Administration. Nine departments including the National Healthcare Security Admi-nistration have issued implementation opinions on expan-ding the regional scope of the pilot program for centralized procurement and use of drugs organized by the state[EB/OL]. （2019-09-30）[2023-09-10].http：//www.nhsa.gov.cn/art/2019/9/30/art_52_1816.htmlhttp://www.nhsa.gov.cn/art/2019/9/30/art_52_1816.html.

邱玥.国家“团购”药品平均降价54%：节约费用超1 000亿元[N].光明日报，2021-01-30（3）.

QIU Y.The average price reduction of national “group buying” drugs is 54%：cost savings exceeding 1 000 billion yuan[N].Guangming Daily，2021-01-30（3）.

谢金平，胡紫馨，王苑如，等.国家药品集中采购政策对四直辖市药品价格、费用及仿制药替代的影响分析[J].中国卫生经济，2021，40（9）：24-28．

XIE J P，HU Z X，WANG Y R，et al. The influences of national centralized drug procurement policy on drug price，cost and generic drug substitution：taking the four municipalities data[J]. Chin Health Econ，2021，40（9）：24-28.

程晟，罗晓，余俊先.药师主导的抗菌药物管理项目对新生儿ICU抗菌药物使用合理性的影响[J].中国医院药学杂志，2019，39（18）：1884-1887.

CHENG S，LUO X，YU J X. Impact of pharmacist-led antimicrobial stewardship program on appropriateness of antibiotic use in neonatal ICU[J]. Chin J Hosp Pharm，2019，39（18）：1884-1887.

吴启胜.药学管理实施前后对合理用药的影响及其不合理用药的原因分析[J].抗感染药学，2018，15（6）：958-960.

WU Q S. Influence of pharmaceutical management on rational drug use before and after implementation and analysis of reasons for irrational drug use[J]. Anti Infect Pharm，2018，15（6）：958-960.

张瑞香，徐宁路.2 400张急诊患者抗菌药物处方用药的相关因素分析[J].抗感染药学，2017，14（3）：514-517.

ZHANG R X，XU N L. Analysis on related factors of antimicrobial medication in 2 400 prescriptions of emergency out-patients[J]. Anti Infect Pharm，2017，14（3）：514-517.

PLENGSURIYAKARN T，NA-BANGCHANG K. Preclinical toxicology and anticholangiocarcinoma activity of oral formulation of standardized extract of Zingiber officinale[J]. Planta Med，2020，86（2）：104-112.

刘婧琳，吴春暖，宋晓坤. 抗肿瘤药物临床超常用药分析[J]. 中国药房，2020，31（7）：873-878.

LIU J L，WU C N，SONG X K. Analysis of abnormal use of anti-tumor drugs in the clinic[J]. China Pharm，2020，31（7）：873-878.

朱姝.新形势下我国生物医药产业面临的机遇与挑战[J].科技中国，2023（8）：17-21.

ZHU S.Opportunities and challenges faced by China’s biomedical industry under the new situation[J].Scitech China，2023（8）：17-21.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰